Nuvectis Pharma, Inc. (NVCT) Wins China Breakthrough Therapy for NXP200
Nuvectis said China’s CDE granted Breakthrough Therapy Designation to NXP200 for BRAF V600—mutant, recurrent or progressive high—grade glioma. Nuvectis holds ex—Greater China rights and plans a U.S. IND submission in Q4 2026.Material DetailsContext by AI AnalystThis is an early-to-mid stage regulat…